| Cardiovascular Risk Management |
1 |
1 |
| Prostate Cancer |
0 |
0.99 |
| Cancer |
0 |
0.92 |
| COVID-19 |
0 |
0.56 |
| Toxicology |
0 |
0.56 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.31 |
| Gonadotropin-Releasing Hormone (GnRH) Antagonist |
0 |
0.24 |
| Clinical Research |
0 |
0.17 |
| Cardiovascular disease |
0 |
0.12 |
| Coronary Artery Disease (CAD) |
0 |
0.12 |
| Europe |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Infarction |
0 |
0.06 |
| Insulin Resistance |
0 |
0.06 |
| LDL Cholesterol |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Other Specialty |
0 |
0.06 |
| Outpatient Clinic |
0 |
0.06 |
| Pandemic |
0 |
0.06 |
| Referral |
0 |
0.06 |
| Cerebrovascular Accident |
0 |
0.05 |
| Health Care Reform |
0 |
0.05 |
| Lipids Management |
0 |
0.05 |
| Myocardial Infarction (MI) |
0 |
0.05 |